Skip to content

Efficacy of Transversus Abdominis Plane Block Versus Local Injection of Pain Medication

Analgesic Efficacy of Transversus Abdominis Plane Block Versus Local Injection in Postoperative Pain Management Following Minimally Invasive Gynecological Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02314104
Enrollment
220
Registered
2014-12-10
Start date
2011-05-31
Completion date
2013-10-31
Last updated
2015-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Keywords

Surgical procedures, Minimally invasive, Nerve block, Anesthetics, Local

Brief summary

The purpose of this study is to determine if there is a better method of administering pain medication prior to minimally invasive gynecological surgery so that postoperative pain and/or narcotic usage may be minimized. Currently, no standard of care exists regarding the use of local pain medications in minimally invasive gynecological surgery and practices vary widely among physicians, even within the same institution. The two methods of preemptive pain medication that this study will be looking at is the transversus abdominis plane (TAP) block and the local injection of pain medication at the areas of the skin incisions. TAP block is a procedure performed by a specially trained pain management anesthesiologist in which there is an injection of a local pain medication into the abdominal wall, specifically in a space where the nerves that are responsible for postoperative pain reside. This procedure blocks the ability of the nerves to sense pain and has been found to be successful in decreasing postoperative pain in a number of procedures. The local injection of pain medications at the incision sites has also been found to be beneficial in decreasing postoperative pain. However, it is not known whether one method is superior to the other in decreasing postoperative pain or if the combination of both is best. Patients that chose to participate are randomly (by chance) assigned to one of three groups: 1) TAP block with pain medication and local injection of normal saline (water) at the incision sites 2) TAP block with normal saline and local injection of pain medication at the incision sites or 3) TAP block with pain medication and local injection of pain medication at the port sites. These procedures are performed while the patient is asleep. Patients will be asked to record their level of pain on a standardized pain scale at one hour, six hours, and twenty-four hours after the surgery. All patients are provided with standard postoperative pain medications as needed. The hypothesis is that patients receiving both TAP block and local injection of pain medication at the port sites will have less pain postoperatively and require a smaller amount of narcotics than those that receive either the TAP block or local injection of pain medication alone.

Detailed description

This is a prospective, single center, double-blinded, multi-arm parallel group study conducted at a university affiliated medical center. Study approval was obtained from the Saint Barnabas Medical Center institutional review board, and written informed consent was obtained from all study participants. Patients were randomly assigned to one of three parallel groups in a 1:1:1 ratio, to receive either: treatment transversus abdominis plane (TAP) block and placebo local injection, placebo TAP block and treatment local injection, or treatment TAP block and treatment local injection. This study took place at Saint Barnabas Medical Center in Livingston, New Jersey from May 2011 to October 2013. Patients were recruited from the offices of ten different gynecological surgeons in private practice. Two of the surgeons were gynecological oncologists, and the remainder were general obstetricians/gynecologists that perform minimally invasive gynecological surgery. The TAP blocks were administered by one of four anesthesiologists. Patients were consented and enrolled in the study by blinded obstetrical and gynecological residents while the patients were in the preoperative area. Each patient was given a standardized informed consent packet detailing the study. Once a patient gave informed consent and was enrolled in the study, independent pharmacists were notified of their enrollment. The pharmacists then assigned participants to one of three possible interventions based on a computer-generated randomization list that was created by the principal investigator prior to commencement of patient enrollment. The pharmacist assigned patients into their appropriate intervention based upon what number participant the patient was in the study. The pharmacist then dispensed the study medications into identical 30 mL syringes labeled study drug and placed them in brown paper bags. The study medication to be administered via TAP block was placed in two 30 mL syringes and placed in a brown paper bag. The study medication to be used for local injection was placed in a single 30 mL syringe and placed in a separate brown paper bag. These bags were then brought to the operating room where they were to be administered. The bag containing the two syringes was given to the anesthesiologists performing the TAP block and the bag with the single syringe was handed to the scrub tech that then later distributed it to the surgeons. The patients, all healthcare providers, and data collectors were blinded as to group allocation. Additionally, both ropivacaine and normal saline are clear and indistinguishable from one another. The interventions were administered in the operating room once the patients had been placed under general anesthesia, prior to skin incisions. The TAP blocks were administered under ultrasound guidance. Patients were then prepped and draped for surgery. Prior to proceeding to skin incisions the surgeons administered 2 mL of local injection subcutaneously at the intended port site locations. If additional port sites were deemed necessary during the procedure study drug was administered in a similar fashion prior to those skin incisions being made. Postoperatively all patients received a standardized analgesia regimen. Specifically, for mild pain, oxycodone/acetaminophen 5/325 mg one tablet orally every four hours; for moderate pain, oxycodone/acetaminophen 5/325 mg two tablets orally every six hours, and for severe pain, hydromorphone 1 mg every 3 hours intravenously.

Interventions

DRUGropivacaine

Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.

Sponsors

Liberman, Eric, D.O.
Lead SponsorINDIV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Female * Undergoing gynecological robotic and/or laparoscopic surgery * Overnight hospitalization expected

Exclusion criteria

* Fibromyalgia * Chronic pelvic pain * Relevant drug allergy * Conversion to laparotomy * Pregnant

Design outcomes

Primary

MeasureTime frameDescription
Postoperative Pain on a Visual Analogue Pain Scale at One Hour Postoperativelyone hour postoperativelyA Visual Analogue Scale was used. The scale range was 0 to 10 in increments of one. 0 was no pain and 10 was worst pain possible.
Postoperative Pain on a Visual Analogue Pain Scale at Six Hours Postoperativelysix hours postoperativelyA Visual Analogue Scale was used. The scale range was 0 to 10 in increments of one. 0 was no pain and 10 was worst pain possible.
Postoperative Pain on a Visual Analogue Pain Scale at Twenty-four Hours Postoperativelytwenty-four hours postoperativelyA Visual Analogue Scale was used. The scale range was 0 to 10 in increments of one. 0 was no pain and 10 was worst pain possible.

Secondary

MeasureTime frame
Time Until First Request for Pain Medicationup to twenty-four hours postoperatively
Total Narcotic Usage in Morphine Equivalentsup to twenty-four hours postoperatively

Countries

United States

Participant flow

Participants by arm

ArmCount
Treatment TAP, Placebo Local Injection
Treatment TAP block was 30 mL 0.5% ropivacaine bilaterally. Placebo local injection was 2 mL of 0.9% normal saline at each port site. ropivacaine: Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
61
Placebo TAP, Treatment Local Injection
Placebo TAP was 30 mL of 0.9% normal saline bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. ropivacaine: Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
63
Treatment TAP, Treatment Local Injection
Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. ropivacaine: Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
59
Total183

Baseline characteristics

CharacteristicTreatment TAP, Placebo Local InjectionPlacebo TAP, Treatment Local InjectionTreatment TAP, Treatment Local InjectionTotal
Age, Continuous53.8 years
STANDARD_DEVIATION 11.3
52.0 years
STANDARD_DEVIATION 9.9
56.1 years
STANDARD_DEVIATION 11
54.0 years
STANDARD_DEVIATION 10.7
BMI (m/kg2)30.5 kg/m^2
STANDARD_DEVIATION 7.4
31.9 kg/m^2
STANDARD_DEVIATION 7
29.9 kg/m^2
STANDARD_DEVIATION 7.5
30.8 kg/m^2
STANDARD_DEVIATION 7.3
Height (inches)64 inches
STANDARD_DEVIATION 2.6
64.7 inches
STANDARD_DEVIATION 2.5
64.1 inches
STANDARD_DEVIATION 2.5
64.3 inches
STANDARD_DEVIATION 2.5
Region of Enrollment
United States
61 participants63 participants59 participants183 participants
Sex: Female, Male
Female
61 Participants63 Participants59 Participants183 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants
Weight (kg)80.8 kg
STANDARD_DEVIATION 20.5
85.9 kg
STANDARD_DEVIATION 18.4
79.2 kg
STANDARD_DEVIATION 20
82.0 kg
STANDARD_DEVIATION 19.6

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
0 / 710 / 780 / 71
serious
Total, serious adverse events
0 / 710 / 780 / 71

Outcome results

Primary

Postoperative Pain on a Visual Analogue Pain Scale at One Hour Postoperatively

A Visual Analogue Scale was used. The scale range was 0 to 10 in increments of one. 0 was no pain and 10 was worst pain possible.

Time frame: one hour postoperatively

ArmMeasureValue (MEAN)Dispersion
Treatment TAP, Placebo Local InjectionPostoperative Pain on a Visual Analogue Pain Scale at One Hour Postoperatively4.04 units on a scaleStandard Deviation 2.9
Placebo TAP, Treatment Local InjectionPostoperative Pain on a Visual Analogue Pain Scale at One Hour Postoperatively5.09 units on a scaleStandard Deviation 2.46
Treatment TAP, Treatment Local InjectionPostoperative Pain on a Visual Analogue Pain Scale at One Hour Postoperatively4.4 units on a scaleStandard Deviation 2.53
Primary

Postoperative Pain on a Visual Analogue Pain Scale at Six Hours Postoperatively

A Visual Analogue Scale was used. The scale range was 0 to 10 in increments of one. 0 was no pain and 10 was worst pain possible.

Time frame: six hours postoperatively

Population: Arm 2: 6 hour pain score not obtained on one subject Arm 3: 6 hour pain score not obtained on one subject

ArmMeasureValue (MEAN)Dispersion
Treatment TAP, Placebo Local InjectionPostoperative Pain on a Visual Analogue Pain Scale at Six Hours Postoperatively3.53 units on a scaleStandard Deviation 2.62
Placebo TAP, Treatment Local InjectionPostoperative Pain on a Visual Analogue Pain Scale at Six Hours Postoperatively3.5 units on a scaleStandard Deviation 1.93
Treatment TAP, Treatment Local InjectionPostoperative Pain on a Visual Analogue Pain Scale at Six Hours Postoperatively3.33 units on a scaleStandard Deviation 2.53
Primary

Postoperative Pain on a Visual Analogue Pain Scale at Twenty-four Hours Postoperatively

A Visual Analogue Scale was used. The scale range was 0 to 10 in increments of one. 0 was no pain and 10 was worst pain possible.

Time frame: twenty-four hours postoperatively

Population: Arm 1: one subject discharged prior to obtaining 24 hour pain score Arm 2: one subject discharged prior to obtaining 24 hour pain score Arm 3: four subjects discharged prior to obtaining 24 hour pain score

ArmMeasureValue (MEAN)Dispersion
Treatment TAP, Placebo Local InjectionPostoperative Pain on a Visual Analogue Pain Scale at Twenty-four Hours Postoperatively3.36 units on a scaleStandard Deviation 2.15
Placebo TAP, Treatment Local InjectionPostoperative Pain on a Visual Analogue Pain Scale at Twenty-four Hours Postoperatively3.56 units on a scaleStandard Deviation 2.13
Treatment TAP, Treatment Local InjectionPostoperative Pain on a Visual Analogue Pain Scale at Twenty-four Hours Postoperatively3.51 units on a scaleStandard Deviation 2.59
Secondary

Time Until First Request for Pain Medication

Time frame: up to twenty-four hours postoperatively

ArmMeasureValue (MEDIAN)
Treatment TAP, Placebo Local InjectionTime Until First Request for Pain Medication46 minutes
Placebo TAP, Treatment Local InjectionTime Until First Request for Pain Medication31 minutes
Treatment TAP, Treatment Local InjectionTime Until First Request for Pain Medication28 minutes
Secondary

Total Narcotic Usage in Morphine Equivalents

Time frame: up to twenty-four hours postoperatively

ArmMeasureValue (MEAN)Dispersion
Treatment TAP, Placebo Local InjectionTotal Narcotic Usage in Morphine Equivalents20.09 mgStandard Deviation 11.6
Placebo TAP, Treatment Local InjectionTotal Narcotic Usage in Morphine Equivalents23.14 mgStandard Deviation 12.3
Treatment TAP, Treatment Local InjectionTotal Narcotic Usage in Morphine Equivalents20.68 mgStandard Deviation 12.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026